Demographics and Baseline Characteristics of Children With Atopic Dermatitis Enrolled in a Randomized Phase 3 Study (TRuE-AD3)

被引：0
|
作者：
Siri, Dareen [1 ]
Lee, Lara Wine [2 ]
Gold, Linda Stein [3 ]
Armstrong, April [4 ]
Brar, Kanwaljit [5 ]
Holland, Kristen [6 ]
Shepard, Julie [7 ]
Devani, Alim [8 ]
Sturm, Daniel [9 ]
Angel, Brett [9 ]
Li, Qian [9 ]
Eichenfield, Lawrence [10 ]
机构：
[1] Midwest Allergy Sinus Asthma, Bloomington, IL USA
[2] Med Univ South Carolina, Charleston, SC USA
[3] Henry Ford Hlth Syst, Detroit, MI USA
[4] Univ Calif Los Angeles, Div Dermatol, Los Angeles, CA USA
[5] NYU Langone Hlth Ctr, Hassenfeld Childrens Hosp, New York, NY USA
[6] Med Coll Wisconsin, Milwaukee, WI USA
[7] Ohio Pediat Res Assoc, Dayton, OH USA
[8] Dermatol Res Inst, Calgary, AB, Canada
[9] Incyte Corp, Wilmington, DE USA
[10] Univ Calif San Diego, San Diego, CA USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
021
引用
收藏
页码：AB8 / AB8
页数：1
相关论文
共 50 条
  • [31] Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant
    Blaiss, Michael
    Dicpinigaitis, Peter
    Birring, Surinder
    McGarvey, Lorcan
    Morice, Alyn
    Pavord, Ian
    Satia, Imran
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB20 - AB20
  • [32] Demographics, Baseline Characteristics, and Disease Symptom Burden in RESPONSE-2: A Randomized, Phase 3 Study of Ruxolitinib in Polycythemia Vera Patients (pts) Who Are Resistant to or Intolerant of Hydroxyurea (HU)
    Passamonti, Francesco
    Criesshammer, Martin
    Cavo, Michele
    Egyed, Milslos
    Benevolo, Giulia
    Devos, Timothy
    Callum, Jeannie
    Vannucchi, Alessandro M.
    Sivgin, Serdar
    Bensasson, Caroline
    Khan, Mahmudul
    Mounedji, Nadjat
    Saydam, Luray
    BLOOD, 2015, 126 (23)
  • [33] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
    Katoh, Norito
    Ikeda, Masanori
    Ohya, Yukihiro
    Murota, Hiroyuki
    Hu, Xiaofei
    Liu, John
    Niiyama, Hayato
    Sasaki, Takuya
    Raymundo, Eliza M.
    Saeki, Hidehisa
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 213 - 232
  • [34] Efficacy and safety of ruxolitinib cream for the treatment of vitiligo by patient demographics and baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies
    Rosmarin, David
    Ezzedine, Khaled
    Desai, Seemal R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB50 - AB50
  • [35] Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America
    Jensen, Rigmor Hoejland
    Tassorelli, Cristina
    Oakes, Tina M. Myers
    Bardos, Jennifer N.
    Zhou, Chunmei
    Dong, Yan
    Aurora, Sheena K.
    Martinez, James M.
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [36] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study
    Norito Katoh
    Masanori Ikeda
    Yukihiro Ohya
    Hiroyuki Murota
    Xiaofei Hu
    John Liu
    Hayato Niiyama
    Takuya Sasaki
    Eliza M. Raymundo
    Hidehisa Saeki
    Dermatology and Therapy, 2024, 14 : 213 - 232
  • [37] Dupilumab in children aged ≥6 to <12 years significantly improves severe atopic dermatitis: results from phase 3 trial (LIBERTY AD PEDS)
    Gooderham, M.
    Boguniewicz, M.
    Sher, L.
    Weisman, J.
    Bansal, A.
    Staudinger, H. W.
    Worrell, R.
    Patel, N.
    Graham, N. M. H.
    Ruddy, M.
    Sun, X.
    Beazley, B.
    Shumel, B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 59 - 60
  • [38] Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
    Werth, Victoria
    Oddis, Chester
    Fiorentino, David
    Dgetluck, Nancy
    Quinn Dinh
    Tillinger, Michael
    White, Barbara
    Lundberg, Ingrid
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [39] Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
    Deleuran, Mette
    Guttman-Yassky, Emma
    Kingo, Kulli
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Akinlade, Bolanle
    Eckert, Laurent
    Gadkari, Abhijit
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB132 - AB132
  • [40] Baricitinib in patients with moderate-tosevere atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
    Simpson, Eric L.
    Forman, Seth
    Silverberg, Jonathan, I
    Zirwas, Matthew
    Maverakis, Emanual
    Han, George
    Guttman-Yassky, Emma
    Marnell, Daniel
    Bissonnette, Robert
    Waibel, Jill
    Nunes, Fabio P.
    DeLozier, Amy M.
    Angle, Robinette
    Gamalo, Margaret
    Holzwarth, Katrin
    Goldblum, Orin
    Zhong, Jinglin
    Janes, Jonathan
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 62 - 70
12345